Endocrinology
Calcium carbonate
Brand: Cal-500
PBAC's latest decision on Calcium carbonate: Recommended (2019). Considered for Treatment of hyperphosphataemia associated with chronic renal failure.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
2019 → 2019
Eligible population
Patients with hyperphosphataemia associated with chronic renal failure.
- Therapy area
- Endocrinology
- Line of therapy
- Not applicable
- Evidence base
- Cost-minimisation
- Primary endpoint
- Cost-minimisation
- Economic model
- Cost-minimisation
- ICER note
- Not modelled — minor submission (pack size change only).
Similar precedents
Open on full dashboard →